Expanding Options for Patients With Acute Myeloid Leukemia: Guidance to Optimize Current and Evolving Therapeutic Approaches

In this program experts review the recommended guidelines for managing acute myeloid leukemia including the latest data on emerging therapies. Download the slidesets from a live CME/CE/CPE-certified webinar and read an expert commentary.

Share

Program Content

Activities

Tx for AML without Biomarkers
Selecting Therapy for AML Without Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 28, 2022

Expires: July 27, 2023

AML Targeted Therapy
Selecting Therapy for AML with Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 28, 2022

Expires: July 27, 2023

AML Emerging Tx
Panel Discussion: New and Novel Advances in AML Therapeutics
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 28, 2022

Expires: July 27, 2023

Activities

Evolving AML Therapy
Experts Answer Questions on Optimizing Therapeutic Approaches in AML
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 07, 2022

Expires: September 06, 2023

Faculty

cover img faculity

Naval G. Daver, MD

Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Genentech, a member of the Roche Group

Jazz Pharmaceuticals, Inc.